"A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation"

drug protocol number
CINC424G12201
drug sponsor
Novartis
drug study
ruxolitinib
drug trial site
KFSH&RC-R
drug status
Completed
drug phase